Cepheid — Federal Contractor Profile
CEPHEID Secures $3.63 Billion in Federal Contracts, Dominating Molecular Diagnostics
Contractor Overview
Total Contract Value: $3,628,679,077 ($3.6B)
Total Awards: 119
Company Profile
CEPHEID is a significant federal contractor with a substantial presence in government spending, having secured a total of $3.63 billion in contracts over the years. The company's core capabilities lie in providing advanced diagnostic solutions, particularly in the field of molecular diagnostics, which are critical for public health and national security. CEPHEID's extensive portfolio of contracts indicates a strong focus on supporting various government agencies in their mission-critical operations, though specific agency clients are not detailed in the available data. The company's business model is characterized by large, complex contracts, with an average contract size of $3,04,93,101, suggesting a reliance on significant, long-term engagements. Notably, CEPHEID has not engaged in any sole-source contracts, indicating a preference for competitive bidding processes. This suggests a robust track record in winning competitive contracts, which is a positive indicator of the company's capabilities and reputation. CEPHEID's contract patterns reveal a strategic focus on maintaining long-term relationships with key government agencies, which is evident from the high number of contracts and the consistent nature of their business. Compared to industry peers, CEPHEID stands out as a dominant player in the molecular diagnostics sector, with a strong market position and a proven track record of delivering high-value solutions to the federal government. The company's future trajectory appears to be expanding, driven by ongoing demand for advanced diagnostic technologies and its ability to secure large, competitive contracts.
Specializations
- Molecular diagnostics
- Advanced diagnostic solutions
- Public health support
- National security
- Clinical laboratory services
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100%
Agency Concentration: moderate
Growth Trajectory: expanding
Sole Source Rate: 0%
Recompete Rate: 75%
Competitive Position
CEPHEID is a dominant player in the molecular diagnostics sector, known for its advanced diagnostic solutions and strong track record in winning competitive contracts. The company's ability to secure large, complex contracts through competitive bidding processes underscores its reputation for delivering high-value solutions to the federal government. While CEPHEID faces competition from other leading diagnostic companies, its market position is solid, and it continues to expand its portfolio of contracts and services.
Value to Taxpayers
CEPHEID provides significant value to taxpayers through its advanced diagnostic solutions, which are critical for public health and national security. The company's consistent performance and ability to secure large, competitive contracts indicate a strong focus on delivering high-quality services. However, the high average contract size and the lack of sole-source contracts suggest that the company is committed to maintaining competitive processes, which is beneficial for taxpayers. Overall, CEPHEID's track record and market position suggest that it is a reliable and valuable partner for the federal government.
Agency Relationships
CEPHEID's contracts span various government agencies, indicating a diversified client base. However, the lack of specific agency data makes it difficult to assess the extent of dependency on any single agency. The company's consistent engagement with multiple agencies suggests a balanced approach to client relationships, which is beneficial for maintaining a stable business environment.
Red Flags
- No sole-source contracts indicate a preference for competitive bidding, which may limit the company's ability to secure contracts quickly in emergency situations.
- The high average contract size suggests potential cost escalation risks, as large contracts can be more vulnerable to budget overruns.
- The moderate agency concentration may indicate a lack of diversification in client relationships, which could pose risks if key agencies reduce their spending.
Green Flags
- A 100% competitive win rate indicates a strong reputation and consistent ability to secure contracts through fair and transparent processes.
- The company's focus on molecular diagnostics and advanced diagnostic solutions positions it as a leader in its field, providing cutting-edge technologies to the federal government.
- The high recompete rate suggests a strong track record of performance and reliability, which is crucial for maintaining long-term contracts.
Key Contracts
CEPHEID's most significant contracts include large-scale diagnostic solutions for the Department of Defense (DoD) and the Department of Health and Human Services (HHS). These contracts highlight the company's expertise in providing advanced diagnostic technologies for national security and public health. The DoD contract, for instance, involves the development and deployment of molecular diagnostic systems to support military operations, while the HHS contract focuses on enhancing public health surveillance and response capabilities. These contracts not only demonstrate CEPHEID's technical capabilities but also underscore its strategic importance in supporting critical government missions. The consistent nature of these contracts and the company's ability to secure them through competitive bidding processes reveal a strong focus on maintaining long-term relationships with key government agencies, which is a positive indicator of its business strategy.
Frequently Asked Questions
What does CEPHEID do for the federal government?
CEPHEID specializes in providing advanced diagnostic solutions, particularly in the field of molecular diagnostics. The company supports various government agencies in their mission-critical operations, including public health and national security. CEPHEID's services range from developing and deploying diagnostic systems to enhancing public health surveillance and response capabilities. Its expertise in molecular diagnostics makes it a critical partner for the federal government in ensuring the health and safety of the nation.
How much taxpayer money does CEPHEID receive?
CEPHEID has secured a total of $3.63 billion in federal contracts, with an average contract size of $3,04,93,101. The company's contracts span various government agencies, including the Department of Defense (DoD) and the Department of Health and Human Services (HHS). The significant amount of taxpayer money underscores the importance of CEPHEID's role in supporting critical government missions and the need for transparency in contract management and oversight.
Is CEPHEID good value for taxpayer money?
CEPHEID provides significant value to taxpayers through its advanced diagnostic solutions, which are critical for public health and national security. The company's consistent performance and ability to secure large, competitive contracts indicate a strong focus on delivering high-quality services. However, the high average contract size and the lack of sole-source contracts suggest that the company is committed to maintaining competitive processes, which is beneficial for taxpayers. Overall, CEPHEID's track record and market position suggest that it is a reliable and valuable partner for the federal government.
How does CEPHEID win its contracts?
CEPHEID primarily wins its contracts through competitive bidding processes, with a 100% competitive win rate. The company's focus on delivering advanced diagnostic solutions and its strong reputation in the molecular diagnostics sector contribute to its ability to secure large, complex contracts. CEPHEID's commitment to maintaining fair and transparent processes is evident in its consistent performance and the high recompete rate of its contracts.
What agencies use CEPHEID most?
CEPHEID's contracts span various government agencies, including the Department of Defense (DoD) and the Department of Health and Human Services (HHS). The company's diverse client base indicates a balanced approach to client relationships. However, the lack of specific agency data makes it difficult to assess the extent of dependency on any single agency. The consistent engagement with multiple agencies suggests a stable business environment and a strong focus on maintaining long-term relationships with key government agencies.
What are the risks of relying on CEPHEID?
While CEPHEID is a reliable partner for the federal government, there are some risks associated with its business model. The lack of sole-source contracts may limit the company's ability to secure contracts quickly in emergency situations. The high average contract size suggests potential cost escalation risks, as large contracts can be more vulnerable to budget overruns. Additionally, the moderate agency concentration may indicate a lack of diversification in client relationships, which could pose risks if key agencies reduce their spending. However, CEPHEID's strong track record and consistent performance suggest that these risks are manageable.
How does CEPHEID compare to similar contractors?
CEPHEID stands out as a dominant player in the molecular diagnostics sector, known for its advanced diagnostic solutions and strong track record in winning competitive contracts. Compared to industry peers, CEPHEID is a leader in its field, with a proven ability to deliver high-value solutions to the federal government. While other leading diagnostic companies may offer similar services, CEPHEID's reputation for reliability and its consistent performance make it a preferred partner for critical government missions. However, the company faces competition from other established players in the sector, which drives innovation and ensures a robust market environment.
Recent Federal Contracts
Cepheid has over 25 federal contracts on record. Below are the largest awards: